Related Research Articles
Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes,fever,drenching sweats,unintended weight loss,itching,and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.
Adult T-cell leukemia/lymphoma is a rare cancer of the immune system's T-cells caused by human T cell leukemia/lymphotropic virus type 1 (HTLV-1). All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. A small amount of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL development. ATL is categorized into 4 subtypes:acute,smoldering,lymphoma-type,chronic. Acute and Lymphoma-type are known to particularly be aggressive with poorer prognosis.
Bevacizumab,sold under the brand name Avastin among others,is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer,it is given by slow injection into a vein (intravenous) and used for colon cancer,lung cancer,ovarian cancer,glioblastoma,hepatocellular carcinoma,and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers,including leukemias,lymphomas,breast,stomach,uterine,ovarian,bladder cancer,and lung cancers. The first anthracycline discovered was daunorubicin,which is produced naturally by Streptomyces peucetius,a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin,daunorubicin,epirubicin and idarubicin.
Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer,others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine,targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth,rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals,the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However,the modalities can be combined;antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.
Adjuvant therapy,also known as adjunct therapy,adjuvant care,or augmentation therapy,is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed,but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery,then further treatment is not technically adjuvant.
MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result,high-risk or low-risk classification,and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.
Breast cancer chemotherapy refers to the use of cytotoxic drugs (chemotherapy) in the treatment of breast cancer.
Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER),progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.
Febrile neutropenia is the development of fever,often with other signs of infection,in a patient with neutropenia,an abnormally low number of neutrophil granulocytes in the blood. It is an oncologic emergency,and is the most common serious complication in patients with hematopoietic cancers or receiving chemotherapy for cancer. The term neutropenic sepsis is also applied,although it tends to be reserved for patients who are less well. In 50% of cases,an infection is detectable;bacteremia is present in approximately 20% of all patients with this condition.
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly,usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.
Oncology is a branch of medicine that deals with the study,treatment,diagnosis,and prevention of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος(ónkos),meaning "tumor","volume" or "mass". Oncology is concerned with:
Lenvatinib,sold under the brand name Lenvima among others,is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1,VEGFR2 and VEGFR3 kinases.
Cancer treatments are a wide range of treatments available for the many different types of cancer,with each cancer type needing its own specific treatment. Treatments can include surgery,chemotherapy,radiation therapy,hormonal therapy,targeted therapy including small-molecule drugs or monoclonal antibodies,and PARP inhibitors such as olaparib. Other therapies include hyperthermia,immunotherapy,photodynamic therapy,and stem-cell therapy. Most commonly cancer treatment involves a series of separate therapies such as chemotherapy before surgery. Angiogenesis inhibitors are sometimes used to enhance the effects of immunotherapies.
High-dose chemotherapy and bone marrow transplant (HDC/BMT),also high-dose chemotherapy with autologous bone marrow transplant,was an ineffective treatment regimen for metastatic breast cancer,and later high-risk breast cancer,that was considered promising during the 1980s and 1990s. With an overall idea that more is better,this process involved taking cells from the person's bone marrow to store in a lab,then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed,and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment,and to have significantly higher side effects,including treatment-related death.
Kathleen I. Pritchard,is the head of oncology at Sunnybrook Health Sciences Centre in Toronto,Canada,specializing in breast cancer therapies,and leading the clinical trials division of the centre. She has authored numerous studies on women's health,breast cancer,hormone replacement therapy,public health,and research methodology. According to Thomson Reuters,Pritchard was one of the most cited researchers in the world in 2014 and 2015.
Maryam Beheshti Lustberg is an American breast oncologist. She is the Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. Lustberg previously served as the Medical Director of Supportive Care at Ohio State's Comprehensive Cancer Center and President-Elect of the Multinational Association of Supportive Care in Cancer. She is also an associate editor for the peer-reviewed medical journal covering oncology nursing with respect to cancer survivors called Journal of Cancer Survivorship. Lustberg was also recognized as one of the 100 Influential Women in Oncology by OncoDaily.
The European School of Oncology (ESO) is a provider of continuing medical education to oncology professionals,with a particular focus on areas of Central and Eastern Europe and the Balkans region.
High-dose chemotherapy (HDC) is referring to chemotherapy medicines which are given at larger dosages than that are usually used in normal chemotherapy regimens. This therapeutic strategy is used to treat some cancers,especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body,HDC seeks to optimize the death of cancer cells.
References
- 1 2 3 "Gary Herbert Lyman | Duke Department of Medicine". medicine.duke.edu. Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- ↑ "Gary Lyman". scholar.google.com. Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- ↑ Balducci, Lodovico; Lyman, Gary H.; Ershler, William B.; Balducci, Lodovico; Ershler, William B.; Lyman, Gary H.; Extermann, Martine, eds. (2004). Comprehensive Geriatric Oncology. doi:10.3109/9780203494516. ISBN 978-0-429-26169-5.[ non-primary source needed ][ page needed ]
- 1 2 "Breast cancer: Translational Therapeutic Strategies". Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- 1 2 "Cancer supportive care : advances in therapeutic strategies". Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- 1 2 "Hematopoietic Growth Factors in Oncology". Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- 1 2 "Special recognitions: April–Sept 2010". Duke Department of Medicine. October 18, 2010. Archived from the original on April 22, 2024. Retrieved April 22, 2024.
- ↑ "HEARING BEFORE THE SUBCOMMITTEE ON HEALTH OF THE COMMITTEE ON FINANCE UNITED STATES SENATE ONE HUNDREDTH CONGRESS" (PDF). Archived (PDF) from the original on 2022-09-20. Retrieved 2024-04-22.
- ↑ Lyman, Gary H.; Abella, Esteban; Pettengell, Ruth (June 2014). "Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review". Critical Reviews in Oncology/Hematology. 90 (3): 190–199. doi:10.1016/j.critrevonc.2013.12.006. PMID 24434034.[ non-primary source needed ]
- ↑ "Comprehensive Geriatric Oncology". Archived from the original on 2024-04-22. Retrieved 2024-04-22.
- ↑ "Oxford American Handbook of Oncology".
- ↑ Lyman, Gary H.; Preisler, Harvey D.; Papahadjopoulos, Demetrios (July 1976). "Membrane action of DMSO and other chemical inducers of Friend leukaemic cell differentiation". Nature. 262 (5567): 360–363. Bibcode:1976Natur.262..360L. doi:10.1038/262360a0. PMID 986559.[ non-primary source needed ]
- ↑ Lyman, Gary H.; Williams, Charles C.; Preston, Dennis (31 January 1980). "The Use of Lithium Carbonate to Reduce Infection and Leukopenia during Systemic Chemotherapy". New England Journal of Medicine. 302 (5): 257–260. doi:10.1056/NEJM198001313020503. PMID 6243170.[ non-primary source needed ]
- ↑ Crawford, Jeffrey; Ozer, Howard; Stoller, Ronald; Johnson, David; Lyman, Gary; Tabbara, Imad; Kris, Mark; Grous, John; Picozzi, Vincent; Rausch, Gregory; Smith, Roy; Gradishar, William; Yahanda, Anne; Vincent, Martha; Stewart, Morgan; Glaspy, John (18 July 1991). "Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer". New England Journal of Medicine. 325 (3): 164–170. doi:10.1056/NEJM199107183250305. PMID 1711156.[ non-primary source needed ]
- ↑ Lyman, Gary H. (2 August 1985). "Association of Leukemia With Radium Groundwater Contamination". JAMA: The Journal of the American Medical Association. 254 (5): 621–626. doi:10.1001/jama.1985.03360050059026. PMID 4009896.[ non-primary source needed ]
- ↑ Radon Exposure: Human Health Threat. U.S. Government Printing Office. 1988. hdl:2027/uc1.31210007523580. OCLC 606501750.[ page needed ]
- ↑ Albertini, John J. (11 December 1996). "Lymphatic Mapping and Sentinel Node Biopsy in the Patient With Breast Cancer". JAMA: The Journal of the American Medical Association. 276 (22): 1818–1822. doi:10.1001/jama.1996.03540220042028. PMID 8946902.
- ↑ Balch, Charles M.; Soong, Seng-Jaw; Gershenwald, Jeffrey E.; Thompson, John F.; Reintgen, Douglas S.; Cascinelli, Natale; Urist, Marshall; McMasters, Kelly M.; Ross, Merrick I.; Kirkwood, John M.; Atkins, Michael B.; Thompson, John A.; Coit, Daniel G.; Byrd, David; Desmond, Renee; Zhang, Yuting; Liu, Ping-Yu; Lyman, Gary H.; Morabito, Aberto (15 August 2001). "Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System". Journal of Clinical Oncology. 19 (16): 3622–3634. doi:10.1200/JCO.2001.19.16.3622. PMID 11504744.[ non-primary source needed ]
- ↑ Lyman, Gary H.; Giuliano, Armando E.; Somerfield, Mark R.; Benson, Al B.; Bodurka, Diane C.; Burstein, Harold J.; Cochran, Alistair J.; Cody, Hiram S.; Edge, Stephen B.; Galper, Sharon; Hayman, James A.; Kim, Theodore Y.; Perkins, Cheryl L.; Podoloff, Donald A.; Sivasubramaniam, Visa Haran; Turner, Roderick R.; Wahl, Richard; Weaver, Donald L.; Wolff, Antonio C.; Winer, Eric P. (20 October 2005). "American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer". Journal of Clinical Oncology. 23 (30): 7703–7720. doi:10.1200/JCO.2005.08.001. PMID 16157938.[ non-primary source needed ]
- ↑ Khorana, Alok A.; Kuderer, Nicole M.; Culakova, Eva; Lyman, Gary H.; Francis, Charles W. (May 15, 2008). "Development and validation of a predictive model for chemotherapy-associated thrombosis". Blood. 111 (10): 4902–4907. doi:10.1182/blood-2007-10-116327. PMC 2384124 . PMID 18216292.[ non-primary source needed ]
- ↑ Kuderer, Nicole M; Choueiri, Toni K; Shah, Dimpy P; Shyr, Yu; Rubinstein, Samuel M; Rivera, Donna R; Shete, Sanjay; Hsu, Chih-Yuan; Desai, Aakash; de Lima Lopes, Gilberto; Grivas, Petros; Painter, Corrie A; Peters, Solange; Thompson, Michael A; Bakouny, Ziad; Batist, Gerald; Bekaii-Saab, Tanios; Bilen, Mehmet A; Bouganim, Nathaniel; Larroya, Mateo Bover; Castellano, Daniel; Del Prete, Salvatore A; Doroshow, Deborah B; Egan, Pamela C; Elkrief, Arielle; Farmakiotis, Dimitrios; Flora, Daniel; Galsky, Matthew D; Glover, Michael J; Griffiths, Elizabeth A; Gulati, Anthony P; Gupta, Shilpa; Hafez, Navid; Halfdanarson, Thorvardur R; Hawley, Jessica E; Hsu, Emily; Kasi, Anup; Khaki, Ali R; Lemmon, Christopher A; Lewis, Colleen; Logan, Barbara; Masters, Tyler; McKay, Rana R; Mesa, Ruben A; Morgans, Alicia K; Mulcahy, Mary F; Panagiotou, Orestis A; Peddi, Prakash; Pennell, Nathan A; Reynolds, Kerry; Rosen, Lane R; Rosovsky, Rachel; Salazar, Mary; Schmidt, Andrew; Shah, Sumit A; Shaya, Justin A; Steinharter, John; Stockerl-Goldstein, Keith E; Subbiah, Suki; Vinh, Donald C; Wehbe, Firas H; Weissmann, Lisa B; Wu, Julie Tsu-Yu; Wulff-Burchfield, Elizabeth; Xie, Zhuoer; Yeh, Albert; Yu, Peter P; Zhou, Alice Y; Zubiri, Leyre; Mishra, Sanjay; Lyman, Gary H; Rini, Brian I; Warner, Jeremy L; Abidi, Maheen; Acoba, Jared D.; Agarwal, Neeraj; Ahmad, Syed; Ajmera, Archana; Altman, Jessica; Angevine, Anne H.; Azad, Nilo; Bar, Michael H.; Bardia, Aditya; Barnholtz-Sloan, Jill; Barrow, Briana; Bashir, Babar; Belenkaya, Rimma; Berg, Stephanie; Bernicker, Eric H.; Bestvina, Christine; Bishnoi, Rohit; Boland, Genevieve; Bonnen, Mark; Bouchard, Gabrielle; Bowles, Daniel W.; Busser, Fiona; Cabal, Angelo; Caimi, Paolo; Carducci, Theresa; Casulo, Carla; Chen, James L.; Clement, Jessica M; Chism, David; Cook, Erin; Curran, Catherine; Daher, Ahmad; Dailey, Mark; Dahiya, Saurabh; Deeken, John; Demetri, George D.; DiLullo, Sandy; Duma, Narjust; Elias, Rawad; Faller, Bryan; Fecher, Leslie A.; Feldman, Lawrence E.; Friese, Christopher R.; Fu, Paul; Fu, Julie; Futreal, Andy; Gainor, Justin; Garcia, Jorge; Gill, David M.; Gillaspie, Erin A.; Giordano, Antonio; Glace, (Mary) Grace; Grothey, Axel; Gulati, Shuchi; Gurley, Michael; Halmos, Balazs; Herbst, Roy; Hershman, Dawn; Hoskins, Kent; Jain, Rohit K.; Jabbour, Salma; Jha, Alokkumar; Johnson, Douglas B.; Joshi, Monika; Kelleher, Kaitlin; Kharofa, Jordan; Khan, Hina; Knoble, Jeanna; Koshkin, Vadim S.; Kulkarni, Amit A.; Lammers, Philip E.; Leighton, John C.; Lewis, Mark A.; Li, Xuanyi; Li, Ang; Lo, K.M. Steve; Loaiza-Bonilla, Arturo; LoRusso, Patricia; Low, Clarke A.; Lustberg, Maryam B.; Mahadevan, Daruka; Mansoor, Abdul-Hai; Marcum, Michelle; Markham, Merry Jennifer; Handy Marshall, Catherine; Mashru, Sandeep H.; Matar, Sara; McNair, Christopher; McWeeney, Shannon; Mehnert, Janice M.; Menendez, Alvaro; Menon, Harry; Messmer, Marcus; Monahan, Ryan; Mushtaq, Sarah; Nagaraj, Gayathri; Nagle, Sarah; Naidoo, Jarushka; Nakayama, John M.; Narayan, Vikram; Nelson, Heather H.; Nemecek, Eneida R.; Nguyen, Ryan; Nuzzo, Pier Vitale; Oberstein, Paul E.; Olszewski, Adam J.; Owenby, Susie; Pasquinelli, Mary M.; Philip, John; Prabhakaran, Sabitha; Puc, Matthew; Ramirez, Amelie; Rathmann, Joerg; Revankar, Sanjay G.; Rho, Young Soo; Rhodes, Terence D.; Rice, Robert L.; Riely, Gregory J.; Riess, Jonathan; Rink, Cameron; Robilotti, Elizabeth V.; Rosenstein, Lori; Routy, Bertrand; Rovito, Marc A.; Saif, M. Wasif; Sanyal, Amit; Schapira, Lidia; Schwartz, Candice; Serrano, Oscar; Shah, Mansi; Shah, Chintan; Shaw, Grace; Shergill, Ardaman; Shouse, Geoffrey; Soares, Heloisa P.; Solorzano, Carmen C.; Srivastava, Pramod K.; Stauffer, Karen; Stover, Daniel G.; Stratton, Jamie; Stratton, Catherine; Subbiah, Vivek; Tamimi, Rulla; Tannir, Nizar M.; Topaloglu, Umit; Van Allen, Eli; Van Loon, Susan; Vega-Luna, Karen; Venepalli, Neeta; Verma, Amit K.; Vikas, Praveen; Wall, Sarah; Weinstein, Paul L.; Weiss, Matthias; Wise-Draper, Trisha; Wood, William A.; Xu, Wenxin (Vincent); Yackzan, Susan; Zacks, Rosemary; Zhang, Tian; Zimmer, Andrea J.; West, Jack (June 2020). "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study". The Lancet. 395 (10241): 1907–1918. doi:10.1016/S0140-6736(20)31187-9. PMC 7255743 . PMID 32473681.[ non-primary source needed ]
- ↑ Kuderer, Nicole M.; Desai, Aakash; Lustberg, Maryam B.; Lyman, Gary H. (November 2022). "Mitigating acute chemotherapy-associated adverse events in patients with cancer". Nature Reviews Clinical Oncology. 19 (11): 681–697. doi:10.1038/s41571-022-00685-3. PMID 36221000.[ non-primary source needed ]
- ↑ Lustberg, Maryam B.; Kuderer, Nicole M.; Desai, Aakash; Bergerot, Cristiane; Lyman, Gary H. (August 2023). "Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship". Nature Reviews Clinical Oncology. 20 (8): 527–542. doi:10.1038/s41571-023-00776-9. PMC 10211308 . PMID 37231127.[ non-primary source needed ]
- ↑ "The Thomas C Chalmers Award | Cochrane Community". community.cochrane.org. Archived from the original on 2024-03-11. Retrieved 2024-04-22.